Multicenter randomized double-blind controlled phase III study of hhpg-19K as prophylactic therapy in patients with advanced non-small cell lung cancer (NSCLC) receiving myelosuppressive chemotherapy.
Caicun Zhou(Tongji University), Jielai Xia(Air Force Medical University), Fuxiang Zhou(Wuhan University), Gang Wu(Hubei University of Chinese Medicine), Yi Liu(Ewha Womans University), Yali Li(Qingdao University), Wei Liu(Academy of Military Medical Sciences), Donglin Wang(Shandong University), Jueping Feng(Wuhan Puai Hospital), Jianxing He(First Affiliated Hospital of Guangzhou Medical University), Jianhua Shi(Linyi People's Hospital), Yunchao Huang(North China University of Water Resources and Electric Power), Baolan Li(Capital Medical University), Xia Song(Shanxi Provincial Cancer Hospital), Ping Yu(Sichuan Cancer Hospital), Jianfei Gao(Shenyang Pharmaceutical University), Cheng Huang(Army Medical University), Changshan An(Yanbian University Hospital), Gongyan Chen(Harbin Medical University), Changping Wu(Soochow University)
Cited by 0
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta‐analysis
|Hepatology|2017|876
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension
|New England Journal of Medicine|2021|742